chapter
cover
pharmacolog
chloroquin
hydroxychloroquin
similar
drug
detail
differ
exampl
drug
partial
excret
fece
proport
differ
chloroquin
hydroxychloroquin
gener
whatev
said
chapter
one
drug
assum
appli
unless
otherwis
specifi
ed
drug
deriv
nucleu
refer
retinopathi
caus
term
retinopathi
commonli
use
abbrevi
chapter
collect
abbrevi
refer
term
fi
rst
use
full
form
along
abbrevi
jesuit
proselyt
chile
discov
inca
bark
cinchona
tree
cure
malaria
addit
medicin
qualiti
cinchona
bark
describ
british
dutch
transplant
tree
javan
plantat
earli
product
quinin
payn
describ
use
quinin
treat
system
lupu
erythematosu
sle
alkaloid
contain
cinchona
bark
pamaquin
also
success
use
treat
sle
japanes
armi
occupi
java
world
war
ii
natur
suppli
quinin
lost
synthesi
antimalari
pursu
unit
state
quinacrin
compound
fi
rst
use
unpleas
side
effect
stain
skin
sclera
yellow
manner
indistinguish
icteru
chloroquin
hydroxychloroquin
found
effect
antimalari
discolor
skin
chloroquin
fi
rst
synthes
andersag
ig
farbenindustri
german
effort
fi
nd
drug
better
quinin
german
lost
interest
drug
judg
toxic
use
man
american
restudi
drug
found
effect
malaria
suffi
cientli
safe
hydroxychloroquin
synthes
propos
safer
altern
chloroquin
resist
chloroquin
antimalari
becam
problem
part
world
world
war
ii
observ
servicemen
rash
infl
ammatori
arthriti
took
quinacrin
chloroquin
malaria
prophylaxi
experienc
improv
autoimmun
condit
page
use
quinacrin
treat
arthriti
autoimmun
dermatolog
condit
later
chloroquin
hydroxychloroquin
also
note
favor
affect
patient
rheumatolog
diseas
time
wide
adopt
use
commonli
use
patient
rheumatoid
arthriti
ra
sle
discoid
lupu
erythematosu
polymorph
light
erupt
solar
urticaria
recurr
basal
cell
carcinoma
skin
porphyrea
cutan
tarda
antiphospholipid
antibodi
syndrom
rarer
condit
side
effect
retinopathi
discuss
chap
chapter
cover
aspect
retinopathi
quinacrin
caus
retinopathi
order
frequenc
chloroquin
hydroxychloroquin
quinacrin
chloroquin
retinopathi
fi
rst
describ
hobb
hydroxychloroquin
retinopathi
fi
rst
describ
braunvallon
quinacrin
retinopathi
rare
said
exist
nevertheless
ident
funduscop
appear
describ
parent
molecul
antimalari
quinin
chloroquin
c
chloroquin
quinolin
hydroxychloroquin
hydroxyl
deriv
chloroquin
hydroxychloroquin
molecular
weight
respect
chloroquin
hydroxychloroquin
amphiphil
weak
base
base
two
fuse
aromat
ring
conjug
doubl
bond
nucleu
fig
drug
cross
cell
membran
well
hydroxychloroquin
polar
less
lipophil
diffi
culti
diffus
across
cell
membran
lack
third
benzen
ring
part
acridin
nucleu
quinacrin
fig
literatur
chloroquin
hydroxychloroquin
articl
express
concentr
ngml
other
ml
molecular
weight
chloroquin
hydroxychloroquin
respect
one
mole
chloroquin
weigh
g
one
mole
hydroxychloroquin
solubl
chloroquin
watersolubl
chloroquin
two
basic
group
correspond
quinolin
nitrogen
diethylamino
sidechain
nitrogen
ioniz
constant
respect
physiolog
ph
chloroquin
monoproton
still
solubl
lipid
abl
travers
cell
membran
howev
biproton
chloroquin
occur
lysosom
ph
sequest
prevent
travers
back
cytoplasm
see
chap
although
amount
free
drug
present
plasma
miniscul
physiolog
ph
chloroquin
hydroxychloroquin
quinacrin
side
chain
similar
chloroquin
base
acridin
nucleu
hydroxychloroquin
weigh
g
follow
chloroquin
hydroxychloroquin
equival
ngml
ngml
respect
convers
one
chloroquin
hydroxychloroquin
equival
ml
respect
form
drug
determin
distribut
drug
plasma
tissu
induct
acidosi
increas
concentr
drug
plasma
erythrocyt
chang
drug
concentr
tissu
larg
reservoir
steadi
state
chemic
brand
name
antimalari
drug
list
tabl
chloroquin
diphosph
oral
form
drug
chloroquin
hydrochlorid
form
use
intramuscularli
malariainduc
coma
neither
permit
routin
clinic
use
japan
follow
multipl
lawsuit
retinopathi
hydroxychloroquin
commonli
use
unit
state
chloroquin
rare
use
unit
state
multipl
lawsuit
led
winthrop
laboratori
withdraw
drug
rheumat
indic
continu
commonli
use
canada
mexico
brazil
europ
poland
turkey
south
africa
asia
structureact
studi
mani
deriv
show
halogen
substitut
posit
seven
fig
reduc
pharmacolog
activ
toxic
aryl
rather
alkyl
side
chain
decreas
therapeut
ratio
increas
alkyl
sidechain
length
fi
carbon
decreas
therapeut
ratio
increas
toxic
chloroquin
bind
nucleic
acid
electrostat
forc
hydrogen
bond
van
der
waal
forc
cation
physiolog
ph
bind
ionic
melanin
polyanion
mani
neg
charg
carboxyl
group
orthosemiquinon
group
bind
forc
melanin
includ
van
der
waal
forc
aromat
ring
chloroquin
indol
nuclei
melanin
well
charg
transfer
complex
melanin
act
electron
acceptor
interact
hydroxychloroquin
melanin
parallel
chloroquin
melanin
name
famili
pigment
polyanion
polym
form
oxid
tyrosin
cellular
vesicl
call
melanosom
term
descript
chemic
eumelanin
brown
black
pheomelanin
red
yellow
occur
red
hair
melanin
occur
retin
pigment
epithelium
rpe
eye
inner
ear
substantia
nigra
brain
highest
concentr
eye
function
melanin
eye
absorb
light
prevent
scatter
protect
free
radic
although
choroid
melanin
seem
synthes
throughout
life
melanin
rpe
synthes
brief
interv
fetal
perinat
life
littl
product
thereaft
chiral
carbon
side
chain
arrang
nonsuperimpos
mirror
imag
stereoisom
call
enantiom
label
r
form
clinic
use
racem
mixtur
equal
amount
r
form
enantiom
chloroquin
equipot
vitro
duck
model
malaria
mice
rat
chloroquin
potent
r
chloroquin
possibl
due
stereoselect
distribut
drug
throughout
bodi
chloroquin
highli
bound
plasma
protein
r
chloroquin
versu
sequestr
r
enantiom
ocular
tissu
greater
enantiom
toxic
enantiom
greater
r
enantiom
mammal
enantiom
chloroquin
hydroxychloroquin
excret
kidney
preferenti
compar
r
enantiom
renal
failur
associ
possibl
chloroquin
hydroxychloroquin
toxic
human
r
chloroquin
r
hydroxychloroquin
respect
pharmacokinet
tissu
distribut
nearli
complet
absorpt
oral
dose
occur
within
h
fig
fast
subject
absorpt
oral
chloroquin
hydroxychloroquin
absorpt
rel
unaffect
concomit
ingest
food
howev
intersubject
variabl
report
extent
absorpt
may
explain
part
individu
variabl
effect
toxic
pharmacokinet
chloroquin
hydroxychloroquin
similar
howev
explan
complic
differenti
sequestr
variou
interact
melanin
complex
written
increas
melanin
relat
toxic
other
deni
maintain
agnost
viewpoint
pend
evid
also
possibl
protect
effect
rais
mechan
suggest
melanin
bind
drug
prevent
format
lamellar
bodi
bind
capac
exceed
hypothes
extens
bind
melanin
produc
high
local
gradient
drug
may
import
identifi
cell
type
particularli
affect
exampl
calcul
suggest
effect
concentr
chloroquin
cytoplasm
rpe
may
rang
ml
chloroquin
accumul
uveal
tract
pigment
anim
albino
anim
type
anim
develop
melanin
content
rpe
decreas
age
fi
rst
two
decad
life
averag
cytoplasm
volum
occupi
melanin
age
decreas
thought
occur
degrad
melanin
damag
light
free
radic
complex
granul
contain
melanolysosom
melanolypofuscin
relationship
decreas
melanin
increas
risk
increas
age
intuit
specul
tissu
bodi
continu
evolv
test
detect
drug
plasma
increasingli
sensit
result
estim
pharmacokinet
paramet
vari
wide
year
exampl
termin
halflif
chloroquin
report
various
one
day
addit
dosedepend
kinet
report
other
claim
interpret
aris
artifact
insensit
detect
method
twocompart
model
thought
best
describ
pharmacokinet
model
three
compart
consid
accur
larg
volum
distribut
v
due
extens
sequestr
drug
tissu
plasma
volum
distribut
l
chloroquin
l
hydroxychloroquin
report
normal
bodi
mass
report
volum
distribut
chloroquin
rang
lkg
depend
sensit
method
detect
chloroquin
drug
disposit
proce
three
phasesdistribut
blood
tissu
equilibr
blood
tissu
releas
tissu
back
blood
phase
halfliv
h
day
respect
peak
plasma
concentr
oral
dose
chloroquin
h
thirtythre
drug
plasma
proteinbound
effect
hypoalbuminemia
alter
immunoglobulin
composit
patient
take
well
understood
phase
termin
elimin
greatest
import
use
autoimmun
diseas
given
year
steadyst
level
emphasi
commonli
quot
median
valu
termin
elimin
halflif
day
pharmacokinet
chloroquin
differ
clinic
import
extent
black
white
patient
averag
melanin
content
black
person
estim
g
white
person
estim
mg
impli
melanin
sequestr
larg
factor
system
pharmacokinet
although
drug
continu
elut
melanin
low
level
year
cessat
ingest
lower
daili
dose
chloroquin
hydroxychloroquin
lead
lower
plateau
concentr
plasma
chloroquin
bioavail
elimin
man
singl
dose
chloroquin
given
intraven
blue
circl
oral
solut
yellow
triangl
tablet
purpl
squar
panel
show
plasma
concentr
chloroquin
panel
b
chloroquin
metabolit
near
superposit
three
curv
panel
evid
nearcomplet
absorpt
chloroquin
gastrointestin
tract
slow
elimin
also
indic
data
gustafsson
ml
daili
dose
chloroquin
mgday
produc
plasma
concentr
equilibrium
ml
depend
bodi
mass
depend
time
reach
equilibrium
level
daili
dose
schemat
repres
fig
halflif
reach
steadyst
concentr
daili
dose
one
may
conclud
mechan
drug
elimin
fi
rstorder
process
rather
complic
depend
eliminationr
constant
plasmadrug
concentr
see
chap
p
concentr
tissu
bodi
ingest
vari
pigment
rat
order
concentr
chloroquin
singl
dose
greatest
least
uvea
liver
lung
kidney
vitreou
heart
skin
hair
brain
blood
serum
result
similar
rabbit
human
drug
bind
melanin
explain
differ
pigment
albino
anim
order
concentr
hydroxychloroquin
variou
tissu
albino
rat
similar
except
concentr
albinot
uvea
fall
approxim
level
heart
pigment
mammal
eye
highest
concentr
due
bind
melanin
similar
result
found
chronic
oral
administr
chloroquin
albino
pigment
rat
fig
limit
inform
case
accident
death
person
take
chloroquin
suicid
chloroquin
ingest
indic
similar
distribut
across
variou
tissu
human
tissu
uptak
function
dosag
howev
given
daili
dose
fi
nal
equilibrium
concentr
lower
higher
bodi
mass
similar
relationship
appli
hydroxychloroquin
dose
data
mackenzi
row
one
plateau
concentr
measur
deduc
see
superscript
find
whole
blood
concentr
approxim
fi
time
plasma
concentr
denot
fi
nding
plasma
concentr
approxim
onefi
fth
whole
blood
concentr
denot
b
nonlinear
rat
threefold
increas
dose
lead
increas
hydroxychloroquin
deposit
liver
spleen
use
way
understand
differenti
distribut
across
variou
tissu
consid
ratio
concentr
tissu
compar
plasma
concentr
tabl
concentr
chloroquin
liver
spleen
adren
gland
time
plasma
depend
speci
chosen
studywheth
speci
pigment
albinoticand
regimen
drug
administr
within
singl
organ
larg
differ
drug
concentr
particular
tissu
exampl
chloroquin
concentr
uvea
rat
time
retina
turn
concentr
six
nine
time
vitreou
anoth
exampl
within
skin
concentr
epidermi
corium
concentr
ratio
variat
refl
ect
sequestr
lysosom
melanin
millimolar
level
found
lysosom
melanin
bind
quantiti
weight
berlin
albino
rat
model
chloroquin
mgkg
given
daili
day
yield
mean
plasma
concentr
gl
ng
mean
given
clinic
unimport
differ
tissu
distribut
chloroquin
hydroxychloroquin
ident
dose
hydroxychloroquin
chloroquin
tissu
level
chloroquin
time
hydroxychloroquin
tissueplasma
concentr
ratio
chloroquin
variou
albinot
anim
rang
hydroxychloroquin
analog
tissueplasma
concentr
ratio
rang
contrast
drug
pigment
anim
tissueplasma
concentr
ratio
approxim
remain
human
tissu
year
five
year
last
ingest
chloroquin
chloroquin
metabolit
measur
urin
metabol
dealkyl
liver
fig
determin
metabolit
chloroquin
chloroquin
administ
monkey
label
metabolit
detect
two
import
desethyl
chloroquin
bisdesethyl
chloroquin
pharmacolog
activ
thought
approxim
toxic
parent
compound
differenti
effi
caci
toxic
metabolit
studi
suggest
made
desethylhydroxychloroquin
might
higher
therapeut
ratio
parent
compound
hydroxychloroquin
quinolin
ring
resist
degrad
cytochrom
enzym
cyp
mediat
total
metabol
metabol
chloroquin
hydroxychloroquin
differ
number
metabolit
produc
fig
thirti
percent
oral
dose
metabol
excret
without
metabol
desethylchloroquin
concentr
dose
chloroquin
reach
chloroquin
concentr
bisdesethylchloroquin
concentr
reach
chloroquin
concentr
steadi
state
ratio
chloroquin
desethylchloroquin
ratio
hydroxychloroquin
desethylhydroxychloroquin
inhibit
cytochrom
isoenzym
drug
variat
across
individu
express
isoform
may
explain
variat
level
two
metabolit
ingest
dose
chloroquin
hydroxychloroquin
exampl
ketoconazol
inhibitor
inhibit
format
desethylchloroquin
cimetidin
anoth
inhibitor
increas
halflif
oral
dose
chloroquin
elimin
halfliv
chloroquin
desethylchloroquin
bisdesethylchloroquin
day
halfliv
elimin
desethyl
metabolit
longer
parent
compound
chloroquin
metabolit
found
urin
month
singl
oral
dose
caution
exercis
consid
result
test
anim
model
result
may
translat
directli
human
metabol
exampl
dog
metabol
chloroquin
glucuronid
manner
unlik
speci
lead
rel
short
halflif
excret
kidney
liver
chloroquin
hydroxychloroquin
approxim
excret
unchang
metabol
drug
kidney
excret
unchang
chang
form
fece
slough
skin
store
long
term
lean
bodi
tissu
tabl
kidney
liver
dysfunct
decreas
excret
lead
greater
drug
retent
higher
risk
retinopathi
anur
patient
compar
subject
normal
renal
function
equilibrium
level
chloroquin
higher
hydroxychloroquin
higher
declin
renal
function
may
one
mechan
age
becom
risk
factor
retinopathi
alkalin
urin
decreas
excret
acidifi
cation
urin
oral
ingest
ammonium
chlorid
increas
renal
excret
intramuscular
inject
dimercaprol
also
increas
urinari
excret
chloroquin
neither
approach
adopt
clinic
practic
practic
method
treat
chloroquin
retinopathi
commonli
use
rheumatolog
condit
effect
high
proport
case
fewer
side
effect
gold
azathioprin
penicillamin
levamisol
diagnos
prescrib
rheumatoid
arthriti
ra
sle
togeth
account
case
epidemiolog
survey
found
patient
ra
patient
sle
take
hydroxychloroquin
point
cours
diseas
antimalari
differ
mechan
action
immunomodul
therapi
make
use
combin
therapi
ra
sle
commonli
observ
patient
take
chloroquin
clinic
respons
measur
subject
improv
object
respons
laboratori
measur
activ
daili
live
reduct
fl
are
diseas
although
initi
embrac
mackenzi
patient
milder
form
sle
ra
recent
trend
use
higher
proport
patient
sle
advoc
use
sle
patient
mani
report
pool
patient
take
togeth
assumpt
diseas
drug
taken
immateri
risk
retinopathi
clinic
effi
caci
may
greater
sle
ra
patient
clinic
respons
dramat
erythrocyt
sediment
rate
creactiv
protein
serum
igg
level
typic
decreas
patient
autoimmun
diseas
treat
occasion
longterm
remiss
autoimmun
diseas
possibl
progress
radiolog
document
joint
diseas
sle
use
also
improv
surviv
may
due
antiatherogen
antithrombot
effect
well
benefi
cial
effect
lipid
profi
le
osteoporosi
drug
stop
benefi
cial
effect
last
sever
week
month
diseas
activ
gener
recur
typic
increas
rate
opportunist
infect
chloroquin
prevent
immunolog
respons
antigen
protein
requir
digest
respons
cell
predigest
antigen
peptid
full
effect
may
take
month
develop
attribut
pharmacodynam
mechan
involv
immun
process
requir
observ
time
develop
howev
effect
predict
base
pharmacokinet
time
requir
satur
lysosom
see
chap
delay
onset
therapeut
effect
initi
therapi
shorten
use
higher
load
dose
fi
rst
week
month
price
increas
frequenc
gastrointestin
side
effect
doubl
daili
dose
common
fi
rst
part
cours
rheumatolog
therapi
begin
mainten
dose
lead
slower
onset
action
clinician
give
patient
drug
holiday
summer
way
assess
drug
still
requir
control
diseas
activ
practic
also
reduc
probabl
develop
rheumatologist
frequent
decreas
dose
time
one
seri
patient
patient
begun
mgday
hydroxychloroquin
daili
dose
reduc
time
import
sinc
common
intervent
ophthalmologist
suggest
dosag
reduct
cessat
respons
concern
retinopathi
approxim
patient
sle
patient
ra
eventu
cessat
drug
year
followup
mainli
ineffi
caci
case
ra
diseas
remiss
case
sle
rate
discontinu
highest
fi
rst
year
case
hydroxychloroquin
year
approxim
patient
sle
patient
ra
discontinu
drug
discontinu
hydroxychloroquin
may
less
common
patient
treat
sle
ra
one
seri
overal
discontinu
rate
respect
approxim
patient
stop
treatment
ocular
problem
blur
vision
corneal
deposit
stop
gastrointestin
complaint
rash
side
effect
rate
stop
depend
physician
patient
relationship
physician
patient
will
other
toler
lessthancomplet
control
diseas
activ
degre
side
effect
chloroquin
commonli
given
dose
mgday
prophylaxi
malaria
given
mg
day
treatment
acut
episod
malaria
common
dose
chloroquin
hydroxychloroquin
clinic
use
mgday
respect
regardless
height
weight
patient
cumul
dose
greater
time
use
prophylaxi
treatment
malaria
administ
patient
autoimmun
diseas
dose
excess
larg
respons
greater
preval
report
era
exampl
recommend
mgday
hydroxychloroquin
mgday
chloroquin
accept
dose
adult
weigh
lb
threshold
ibw
dose
recogn
unaccept
recogn
lb
lb
sophist
regimen
seek
dose
greater
mgkgday
base
actual
bodi
weight
abw
mg
kgday
base
ibw
hydroxychloroquin
analog
ceil
chloroquin
mgkgday
base
ibw
prefer
dose
base
ibw
patient
abw
less
ibw
base
height
abw
use
determin
dose
mg
dose
chloroquin
phosphat
contain
mg
chloroquin
base
mg
dose
hydroxychloroquin
sulfat
contain
mg
hydroxychloroquin
base
rel
potenc
toxic
two
inconsist
portray
written
chloroquin
potent
toxic
hydroxychloroquin
other
said
revers
exampl
mg
hydroxychloroquin
assum
equival
mg
chloroquin
yet
anoth
report
assum
mg
chloroquin
equival
mg
hydroxychloroquin
report
state
mg
hydroxychloroquin
equival
mg
chloroquin
best
analysi
base
multipl
form
administr
differ
anim
model
human
trial
chloroquin
hydroxychloroquin
equipot
chloroquin
approxim
twice
toxic
acut
toxic
experi
anim
model
dose
die
ld
approxim
twice
high
hydroxychloroquin
chloroquin
see
chap
likewis
subacut
chronic
toxic
studi
toler
dose
anim
approxim
twice
high
hydroxychloroquin
chloroquin
although
less
rigor
clinic
seri
human
suggest
smaller
percentag
side
effect
hydroxychloroquin
compar
chloroquin
two
given
compar
dosag
therefor
commonli
prescrib
daili
dose
chloroquin
hydroxychloroquin
consid
equal
effect
treat
autoimmun
diseas
therapeut
ratio
favor
hydroxychloroquin
see
chap
report
inconsist
way
report
drug
concentr
plasma
serum
whole
blood
concentr
use
compar
plasma
concentr
lowest
whole
blood
concentr
greatest
serum
concentr
exceed
plasma
concentr
platelet
concentr
upon
coagul
blood
platelet
content
releas
serum
plasma
level
chloroquin
effect
malaria
ml
rheumatolog
diseas
higher
plasma
level
requiredapproxim
ml
serum
concentr
chloroquin
patient
take
chloroquin
mgday
long
period
rang
ml
therapeut
whole
blood
concentr
hc
autoimmun
diseas
ml
approxim
fi
time
higher
plasma
concentr
use
whole
blood
concentr
optim
preferenti
sequest
erythrocyt
leukocyt
impli
hematocrit
white
blood
cell
count
affect
whole
blood
concentr
potenti
confound
way
hand
precis
measur
higher
whole
blood
plasma
possibl
due
technic
difficulti
separ
blood
cell
platelet
plasma
make
whole
blood
suit
pharmacokinet
analys
studi
patient
rheumatoid
arthriti
patient
less
morn
stiff
rheumatoid
factor
signifi
cantli
higher
blood
concentr
hydroxychloroquin
patient
morn
stiff
presenc
rheumatoid
factor
studi
found
correl
plasma
concentr
clinic
respons
patient
take
hydroxychloroquin
ra
sle
daili
dose
mgday
associ
wide
variabl
whole
blood
concentr
studi
patient
sle
patient
inact
diseas
averag
whole
blood
concentr
ml
compar
patient
activ
diseas
higher
rate
effi
caci
assur
dose
calibr
yield
whole
blood
concentr
approxim
ml
variabl
may
due
lack
adher
therapi
differ
absorpt
metabol
drug
individu
interindividu
variabl
certain
patient
may
possibl
reach
therapeut
concentr
without
exceed
daili
dose
threshold
base
ibw
consid
high
risk
caus
retinopathi
patient
take
hydroxychloroquin
graftversushost
diseas
higher
whole
blood
concentr
target
ml
concern
retinopathi
patient
balanc
seriou
natur
system
diseas
effect
plasma
concentr
effect
vitro
concentr
drug
necessarili
close
relat
drug
concentr
may
higher
local
due
intracellular
organel
sequestr
potenti
confound
includ
receptor
concentr
infl
uenc
alcohol
smoke
genet
gender
infl
uenc
age
perhap
inconsist
result
clinician
measur
plasma
concentr
judg
adequaci
trial
drug
one
therapeut
strategi
use
reduc
risk
retinopathi
yet
obtain
benefi
cial
diseas
modifi
effect
antimalari
therapi
combin
chloroquin
hydroxychloroquin
quinacrin
consid
lesser
risk
caus
retinopathi
practic
term
patient
begun
hydroxychloroquin
mgday
mgkgday
base
ibw
whichev
lower
month
autoimmun
diseas
suffi
cientli
respond
quainacrin
mgday
ad
one
addit
month
respons
achiev
hydroxychloroquin
reduc
mgday
although
risk
retinopathi
quinacrin
less
retinopathi
associ
infrequ
quinacrin
antimalari
cross
placenta
concentr
eye
fetal
anim
mice
monkey
model
cord
blood
concentr
antimalari
similar
matern
blood
level
toxic
fetu
report
howev
number
mother
taken
one
drug
daili
basi
pregnant
whose
offspr
subsequ
examin
retinopathi
small
method
check
retinopathi
insensit
tabl
random
control
trial
greater
pregnanc
per
arm
would
requir
detect
differ
pregnanc
loss
alpha
error
beta
error
studi
unlik
done
therefor
practic
like
guid
evid
lesser
qualiti
casecontrol
studi
prospect
case
seri
rate
spontan
abort
fetal
death
fetal
distress
congenit
malform
differ
although
studi
small
littl
power
detect
small
differ
rate
flare
lupu
among
women
stop
pregnanc
frequent
women
continu
drug
throughout
pregnanc
gener
consensu
mother
use
antimalari
drug
pregnanc
need
stop
appear
affect
fetal
health
dissent
opinion
publish
base
anecdot
associ
fetal
abnorm
mother
take
pregnanc
data
use
antimalari
lactat
mother
spars
small
amount
excret
breast
milk
woman
given
mg
hydroxychloroquin
cours
h
concentr
drug
breast
milk
ml
dose
deliv
breastfeed
infant
estim
mgkgday
far
less
threshold
mgkgday
use
regul
pediatr
adult
dose
littl
evid
avail
suggest
breastfeed
mother
may
continu
therapi
hydroxychloroquin
chloroquin
prescript
consid
pregnanc
hydroxychloroquin
prefer
chloroquin
may
less
toxic
hydroxychloroquin
use
treatment
antiphospholipid
syndrom
hydroxychloroquin
less
concentr
breast
milk
chloroquin
mechan
action
mechan
action
chloroquin
hydroxychloroquin
thought
mechan
receiv
attent
involv
lysosomotrop
properti
accumul
within
lysosom
intracellular
acid
compart
due
proton
sequestr
drug
uncharg
readili
diffus
lysosom
proton
two
basic
residu
diffus
back
cytoplasm
lysosom
ph
four
fi
maintain
activ
transport
proton
cytosol
lysosom
cytosol
extracellular
milieu
ph
approxim
chloroquin
weak
base
p
k
amin
group
posit
seven
p
k
amin
group
alkyl
side
chain
lysosom
concentr
chloroquin
high
ml
measur
ph
lysosom
expos
chloroquin
increas
baselin
four
six
ph
gradient
abolish
chloroquin
accumul
ceas
bafi
lomycin
inhibitor
lysosom
acidifi
cation
block
chloroquineinduc
lysosomotrop
toxic
cell
cultur
equilibrium
ratio
distribut
diacid
base
lysosom
plasma
given
ratio
h
l
h
p
h
l
hydrogen
ion
concentr
lysosom
h
p
hydrogen
ion
concentr
plasma
thu
ratio
lysosom
plasma
approxim
maintain
osmot
balanc
chloroquin
enter
lysosom
water
accompani
swell
organel
although
lysosom
small
fraction
intracellular
volum
larg
gradient
suggest
larg
volum
distribut
empir
measur
pharmacokinet
studi
see
sect
besid
sequestr
due
diproton
also
bind
acid
polysaccharid
acid
glycolipid
found
lysosom
membran
inhibit
lysosom
enzymat
function
hypothes
caus
benefi
cial
effect
retinopathi
insid
lysosom
inhibit
lysosom
activ
cathepsin
b
enzym
involv
degrad
mucopolysaccharid
protein
elev
lysosom
ph
inhibit
mhc
class
iidepend
antigen
process
present
monocyt
rais
ph
increas
invari
chain
ii
dissoci
mhc
class
ii
molecul
via
decreas
activ
aspartyl
proteas
cathepsin
cathepsin
b
cleav
ii
mhc
class
ii
molecul
decreas
antigen
bind
surfac
profession
apc
see
chap
also
inhibit
lysosom
pinocytosi
inhibit
digest
exogen
protein
antigen
peptid
decreas
peptid
load
groov
chain
mhc
class
ii
molecul
fewer
peptidemhc
class
ii
complex
transport
cell
surfac
present
cell
see
chap
selfantigen
typic
lower
affi
niti
mhc
class
ii
molecul
nonselfantigen
thu
preferenti
inhibitori
effect
autoimmun
impair
immun
exogen
agent
net
effect
dysfunct
protein
process
receptor
recycl
protein
secret
reduc
product
cytokin
immun
mediat
reduc
lymphocyt
product
reduc
natur
killer
cell
activ
toxic
effect
occur
lysosom
expos
accumul
ubiquitin
protein
lead
apoptosi
disrupt
autophagi
oxid
injuri
swollen
lysosom
combin
phagosom
contain
photoreceptor
outer
segment
form
lamellar
inclus
bodi
myeloid
myelin
bodi
see
chap
increas
lysosom
ph
inhibit
receptorenzym
dissoci
may
toxic
effect
sequest
cell
membran
includ
protein
receptor
myelin
bodi
disrupt
normal
recycl
deplet
popul
surfac
membran
receptor
without
chang
receptor
affi
niti
disrupt
interact
retin
neuron
rpe
cell
local
environ
result
toxic
eventu
morpholog
damag
although
lysosomotrop
effect
receiv
attent
affect
mani
cellular
process
confus
tie
togeth
comprehens
way
one
way
organ
depend
concentr
author
contend
mechan
depend
concentr
higher
ml
vitro
relev
clinic
effect
reason
concentr
higher
expect
found
clinic
plasma
exampl
although
hydroxychloroquin
concentr
ml
affect
cytokin
level
produc
peripher
blood
mononuclear
cell
patient
ra
sle
vitro
uncertain
physiolog
pathway
anoth
exampl
signifi
cant
inhibit
immunoglobulin
synthesi
secret
rat
plasma
cell
vitro
requir
concentr
ml
chloroquin
level
drug
present
whole
blood
plasma
possibl
level
relev
intracellular
compart
known
higher
concentr
plasma
livertoplasma
ratio
record
rat
model
chloroquin
pharmacokinet
tabl
view
therefor
mechan
oper
concentr
may
clinic
relev
given
persist
controversi
coverag
includ
mechan
found
higher
concentr
group
order
magnitud
tabl
provid
nonexhaust
list
effect
group
concentr
depend
chloroquin
inhibit
interact
memori
b
cell
unprim
b
cell
specifi
c
foreign
antigen
chloroquin
inhibit
dna
synthesi
secret
human
peripher
blood
mononuclear
cell
stimul
foreign
antigen
attach
ferriprotoporphyrin
ix
fp
form
toxic
complex
increas
membran
permeabl
erythrocyt
parasit
malaria
protozoan
protozoan
erythrocyt
protozoan
lost
potassium
swell
lyse
inhibit
profession
apc
stimul
prime
cell
decreas
level
serum
chloroquin
reduc
mrna
level
reduc
stabil
ph
depend
mechan
human
monocyt
cell
cultur
transcript
dna
rna
block
inhibit
express
occur
block
transcript
dna
mrna
mechan
involv
sequestr
chloroquin
lysosom
bafi
lomycin
block
effect
chloroquin
rat
bloodvessel
model
assess
prostaglandin
inhibit
chloroquin
inhibit
prostaglandin
effect
patient
take
chloroquin
sle
ra
circul
lymphocyt
contain
higher
number
myelin
bodi
see
chap
compar
lymphocyt
control
patient
take
drug
nonrheumatoid
control
subject
associ
inhibit
lysosom
enzym
cathepsin
b
phospholipas
chloroquin
also
inhibit
mucopolysaccharidas
alcohol
dehydrogenas
acid
phosphodiesteras
within
lysosom
elev
ph
would
occur
lysosom
expos
chloroquin
increas
inhibitori
potenc
chloroquin
inhibit
leukotrien
releas
human
lung
tissu
cell
cultur
overcom
arachidon
acid
suggest
inhibit
phospholipas
chloroquin
inhibit
c
p
goligodeoxynucleotid
c
p
godn
mediat
blockad
apoptosi
inhibit
secret
murin
b
cell
lymphoma
model
hydroxychloroquin
decreas
hiv
viral
rna
titer
chloroquin
inhibit
polypeptid
synthesi
rat
liver
cell
free
extract
bind
polynucleotid
prevent
subsequ
format
polynucleotideribosom
complex
effect
polypeptid
chain
initi
termin
recur
theme
paper
written
mechan
action
chloroquin
hydroxychloroquin
use
bafi
lomycin
ammonium
acet
ammonium
acet
cation
cross
cellular
membran
easili
use
fl
atten
proton
gradient
across
cell
membran
bafi
lomycin
drug
inhibit
vacuolar
proton
pump
decreas
acidifi
cation
intracellular
vacuol
provid
tool
diminish
uptak
lysosom
dissect
mechan
sever
candid
continu
concentr
rang
relev
chloroquin
inhibit
chemotaxi
polymorphonuclear
leukocyt
chloroquin
inhibit
product
immunoglobulin
secret
cell
respons
staphylococcu
aureu
interf
monocyt
secret
human
peripher
mononuclear
cell
chloroquin
protect
lysosom
ruptur
lysolecithin
progesteron
etiocholanolon
vitamin
streptolysin
ultraviolet
irradi
incub
neutral
ph
stabil
lysosom
membran
inhibit
releas
lysosom
enzym
receptor
recycl
chloroquin
inhibit
cytokin
secret
mononuclear
cell
bind
inositol
intracellular
receptor
inhibit
activ
tolllik
receptor
rais
intralysosom
ph
chloroquin
suppress
secret
catecholamin
bovin
adren
medullari
cell
interf
calcium
uptak
chloroquin
caus
decreas
lysosom
arylsulfatas
activ
cultur
human
fi
broblast
hydroxychloroquin
reduc
bind
antiphospholipid
antibodi
phospholipid
bilay
increas
activ
hmgcoa
reductas
decreas
serum
cholesterol
atherosclerosi
sle
reduc
serum
glucos
incid
diabet
mellitu
sle
antithrombot
effect
sle
aq
prevent
platelet
alphagranul
releas
vitro
inhibit
releas
arachidon
acid
stimul
platelet
chloroquin
inhibit
human
lymphocyt
prolifer
stimul
phytohemagglutinin
conconavalin
effect
occur
drug
ad
earli
cultur
later
indic
action
involv
lysosom
via
dna
bind
chloroquin
inhibit
digest
endocytos
protein
mous
periton
macrophag
chloroquin
inhibit
proteolyt
convers
proform
complement
cultur
rat
hepatocyt
chloroquin
inhibit
phosphoryl
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
chloroquin
inhibit
mitochondri
respir
chloroquin
inhibit
dna
polymeras
chloroquin
competit
inhibit
cholinesteras
plasma
human
red
blood
cell
inhibit
express
cell
surfac
tnf
receptor
without
affect
level
tnf
receptor
mrna
human
histiocyt
lymphoma
cell
line
cultur
human
peripher
monocyt
suggest
inhibit
transport
receptor
cytosol
cell
surfac
chloroquin
inhibit
endotoxinstimul
human
whole
blood
monocyt
effect
dna
transcript
lysosomotrop
mechan
hydroxychloroquin
induc
apoptosi
human
lymphocyt
normal
subject
synoviocyt
taken
ra
patient
chloroquin
inhibit
extracellular
signalregul
kinas
erk
hela
cell
promot
suscept
fasmedi
apoptosi
chloroquin
block
dna
repair
neutrophil
oxid
metabol
inhibit
proteolyt
process
secretori
protein
hepatocyt
inhibit
chloroquin
inhibit
dna
rna
biosynthesi
associ
degrad
ribosom
ribosom
rna
bacteri
model
chloroquin
rais
ph
food
vacuol
malaria
parasit
inhibit
digest
hemoglobin
resist
strain
malaria
accumul
less
chloroquin
nonresist
parasit
inhibit
protein
synthesi
uptak
amino
acid
beef
rpe
cell
cultur
chloroquin
decreas
serum
phospholipid
concomit
appear
multilamellar
myeloid
bodi
rpe
photoreceptor
ganglion
cell
rat
model
concentr
report
inhibit
antigen
present
chemotaxi
phagocytosi
calcium
receptor
signal
b
cell
matrix
metalloproteinas
activ
chloroquin
prevent
cell
respons
antigen
protein
antigen
peptid
impli
mechan
inhibit
cleavag
antigen
protein
macrophag
hydroxychloroquin
increas
fasmedi
apoptosi
synoviocyt
inhibit
gene
express
cell
respons
immun
stimuli
chloroquin
inhibit
autophagi
human
rpe
cell
inhibit
vacuolar
h
atpas
bafi
lomycin
block
effect
impli
chloroquin
act
lysosomotrop
agent
rat
pancrea
model
chloroquin
increas
volum
autophag
vacuol
increas
proteolyt
lysosom
enzym
activ
hydroxychloroquin
inhibit
collageninduc
platelet
aggreg
alphagranul
releas
cholesterol
ester
format
stimul
activ
inhibit
result
ldl
accumul
within
cell
chloroquin
deplet
acid
hydrolas
receptor
cell
surfac
inhibit
pinocytosi
acid
hydrolas
secret
newli
synthes
acid
hydrolas
bear
phosphomannosyl
recognit
marker
increas
chloroquin
increas
nitric
oxid
synthas
activ
endotheli
cell
number
studi
exclud
mechan
produc
effect
hydroxychloroquin
inhibit
cyclooxygenas
decreas
prostaglandin
product
bind
dna
thought
clinic
import
mechan
mefl
oquin
bind
dna
yet
effect
antimalari
drug
benefi
cial
effect
polymorph
light
erupt
due
lightscreen
effect
act
mechan
concentr
rang
relev
chloroquin
reduc
incorpor
label
sulfat
cartilag
polysaccharid
sulfat
rat
model
chloroquin
intercal
base
pair
dna
evidenc
increas
viscos
dna
expos
chloroquin
chloroquin
inhibit
mitogenesi
polymorphonuclear
leukocyt
stimul
zymosan
chloroquin
inhibit
spontan
interferonupregul
natur
killer
activ
patient
ra
interf
bind
antiphospholipid
antibodi
annexin
potent
anticoagul
reduc
lipid
triglycerid
level
increas
lowdens
lipoprotein
receptor
activ
increas
hmgcoa
reductas
activ
reduc
cardiovascular
diseas
risk
decreas
incid
diabet
hypoglycem
effect
decreas
glycosyl
hemoglobin
level
patient
diabet
improv
glucos
toler
patient
type
ii
diabet
inhibit
stimul
macrophag
chloroquin
antineoplast
effect
produc
reduct
incid
burkitt
lymphoma
among
patient
tanzania
took
drug
malaria
chloroquineinduc
apoptosi
malign
b
cell
patient
chronic
lymphocyt
leukemia
hydroxychloroquin
antibreast
cancer
effect
chloroquin
anticolon
cancer
effect
mous
model
induc
cell
death
human
lung
cancer
cell
produc
better
surviv
patient
glioblastoma
multiform
promot
oxid
cystein
residu
peripherinrd
protein
lead
disorgan
photoreceptor
outer
segment
cell
death
chloroquin
direct
depress
effect
smooth
muscl
gut
arteri
trachea
ciliari
bodi
might
explain
mild
ileu
temporari
presbyopia
patient
often
experi
start
drug
inhibit
replic
hiv
sar
coronaviru
infl
uenza
chloroquin
block
product
caus
ultraviolet
irradi
skin
normal
subject
effect
express
cytokin
unirradi
skin
chloroquin
stimul
nitric
oxid
product
kidney
brain
increas
vasopressin
natriuresi
chloroquin
enhanc
cell
respons
apc
solubl
antigen
retinopathi
il
interleukin
ifn
interferon
tnf
tumor
necrosi
factor
dna
deoxyribonucl
acid
rna
ribonucl
acid
sle
system
lupu
erythematosu
ra
rheumatoid
arthriti
rpe
retin
pigment
epithelium
hiv
human
immunodefi
cienci
viru
tlr
tolllik
receptor
hmgcoa
reductas
mrna
mitochondri
ribonucl
acid
ldl
lowdens
lipoprotein
sar
sever
acut
respiratori
syndrom
apc
antigen
present
cell
physic
barrier
passag
ultraviolet
radiat
chloroquin
affect
mitochondri
respir
oxid
phosphoryl
mouseliv
homogen
ratliv
mitochondria
neither
affect
adenosin
triphosph
activ
cow
visual
pigment
extract
chloroquin
affect
intern
oligonucleotid
via
acidifi
ed
vesicl
proton
pump
inhibitor
omeprazol
may
inhibit
accumul
lysosom
decreas
ph
organel
potenti
antagon
effect
drug
immunomodul
effect
hypothes
drug
inhibit
ketoconazol
cimetidin
increas
plasma
level
pharmacolog
chloroquin
hydroxychloroquin
similar
molecular
weight
chloroquin
hydroxychloroquin
respect
chloroquin
hydroxychloroquin
alkyl
water
solubl
weak
amphiphil
base
readili
cross
cell
membran
melanin
bind
weight
whether
protect
exacerb
effect
risk
retinopathi
unknown
lysosomotrop
virtu
proton
trap
insid
acid
lysosom
absorpt
nearli
complet
peak
plasma
concentr
h
oral
dose
volum
distribut
greater
l
termin
elimin
halflif
approxim
day
equilibrium
plasma
concentr
depend
daili
dose
ibw
chronic
ingest
nonalbinot
mammal
tissu
concentr
drug
highest
uvea
rpe
concentr
time
plasma
albinot
mammal
uveal
drug
concentr
approxim
heart
lipophob
concentr
fat
onetenth
plasma
major
metabolit
desethyl
bisdesethyl
deriv
parent
drug
metabolit
pharmacolog
activ
respons
metabol
forti
excret
kidney
excret
fece
slough
skin
store
lean
tissu
renal
hepat
insuffi
cienci
lead
higher
plasma
concentr
given
daili
dose
rais
risk
toxic
clinic
effect
take
month
develop
load
dose
use
time
cours
follow
pharmacokinet
steadyst
concentr
four
hundr
milligram
per
day
hydroxychloroquin
mgday
chloroquin
accept
lesser
patient
ibw
abw
lb
hydroxychloroquin
chloroquin
equipot
chloroquin
toxic
thu
therapeut
ratio
higher
hydroxychloroquin
whole
blood
concentr
approxim
fi
time
plasma
concentr
precis
favor
pharmacokinet
measur
clinic
therapeut
concentr
greater
ml
stop
pregnanc
lactat
action
lysosomotrop
mechan
import
clinic
effect
dichotom
effect
cell
inhibit
cell
stimul
promot
cell
stimul
combin
effect
benefi
cial
action
autoimmun
without
penalti
increas
opportunist
infect
